HomeCompareENZ vs EQR

ENZ vs EQR: Dividend Comparison 2026

ENZ yields 127.47% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENZ wins by $11.24M in total portfolio value
10 years
ENZ
ENZ
● Live price
127.47%
Share price
$0.31
Annual div
$0.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.29M
Annual income
$4,437,918.34
Full ENZ calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — ENZ vs EQR

📍 ENZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENZEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENZ + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENZ pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENZ
Annual income on $10K today (after 15% tax)
$10,834.93/yr
After 10yr DRIP, annual income (after tax)
$3,772,230.59/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, ENZ beats the other by $3,767,576.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENZ + EQR for your $10,000?

ENZ: 50%EQR: 50%
100% EQR50/50100% ENZ
Portfolio after 10yr
$5.67M
Annual income
$2,221,696.97/yr
Blended yield
39.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ENZ
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-5.6
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENZ buys
0
EQR buys
0
No recent congressional trades found for ENZ or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENZEQR
Forward yield127.47%5.87%
Annual dividend / share$0.40$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$11.29M$47.8K
Annual income after 10y$4,437,918.34$5,475.61
Total dividends collected$10.31M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: ENZ vs EQR ($10,000, DRIP)

YearENZ PortfolioENZ Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$23,447$12,746.97$11,380$679.82+$12.1KENZ
2$53,021$27,932.52$13,014$837.25+$40.0KENZ
3$115,764$59,031.74$14,961$1,036.20+$100.8KENZ
4$244,324$120,456.19$17,297$1,289.22+$227.0KENZ
5$499,021$237,595.07$20,121$1,613.15+$478.9KENZ
6$987,484$453,531.34$23,561$2,030.84+$963.9KENZ
7$1,895,362$838,753.88$27,783$2,573.54+$1.87MENZ
8$3,532,609$1,504,571.30$33,013$3,284.39+$3.50MENZ
9$6,400,682$2,620,790.80$39,547$4,223.51+$6.36MENZ
10$11,286,648$4,437,918.34$47,791$5,475.61+$11.24MENZ

ENZ vs EQR: Complete Analysis 2026

ENZStock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Full ENZ Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ENZ vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENZ vs SCHDENZ vs JEPIENZ vs OENZ vs KOENZ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.